BRPI0707769A2 - tratamentos antivirais intravenosos - Google Patents

tratamentos antivirais intravenosos Download PDF

Info

Publication number: BRPI0707769A2
Authority: BR; Brazil
Prior art keywords: formula; compound; pharmaceutically acceptable; use according; acceptable salt
Prior art date: 2006-02-13

Application number

BRPI0707769-6A

Other languages

English (en)

Portuguese (pt)

Inventor

Yarlagadda Sudhakara Babu

Pooran Chand

Shanta Bantia

Shane Arnold

John Michael Kilpatrick

Original Assignee

Biocryst Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-02-13

Filing date

2007-02-12

Publication date

2011-05-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38169715&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0707769(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-04-12 Priority claimed from PCT/US2006/013535 external-priority patent/WO2007117241A1/en

2007-02-12 Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc

2011-05-10 Publication of BRPI0707769A2 publication Critical patent/BRPI0707769A2/pt

Links

238000001990 intravenous administration Methods 0.000 title claims abstract description 48
230000000840 anti-viral effect Effects 0.000 title claims abstract description 14
238000011282 treatment Methods 0.000 title abstract description 13
238000000034 method Methods 0.000 claims abstract description 48
208000036142 Viral infection Diseases 0.000 claims abstract description 17
239000002552 dosage form Substances 0.000 claims abstract description 17
230000009385 viral infection Effects 0.000 claims abstract description 17
150000001875 compounds Chemical class 0.000 claims description 146
150000003839 salts Chemical class 0.000 claims description 87
241000700605 Viruses Species 0.000 claims description 51
241000712461 unidentified influenza virus Species 0.000 claims description 46
239000003814 drug Substances 0.000 claims description 41
229940079593 drug Drugs 0.000 claims description 31
229940123424 Neuraminidase inhibitor Drugs 0.000 claims description 29
230000002401 inhibitory effect Effects 0.000 claims description 29
239000002911 sialidase inhibitor Substances 0.000 claims description 29
230000036470 plasma concentration Effects 0.000 claims description 19
206010022000 influenza Diseases 0.000 claims description 18
208000024891 symptom Diseases 0.000 claims description 17
208000015181 infectious disease Diseases 0.000 claims description 16
239000003112 inhibitor Substances 0.000 claims description 15
241000282412 Homo Species 0.000 claims description 14
238000010253 intravenous injection Methods 0.000 claims description 13
238000004519 manufacturing process Methods 0.000 claims description 13
239000000203 mixture Substances 0.000 claims description 13
241000271566 Aves Species 0.000 claims description 11
238000002347 injection Methods 0.000 claims description 11
239000007924 injection Substances 0.000 claims description 11
241000124008 Mammalia Species 0.000 claims description 10
238000010255 intramuscular injection Methods 0.000 claims description 9
239000007927 intramuscular injection Substances 0.000 claims description 9
102000005348 Neuraminidase Human genes 0.000 claims description 6
108010006232 Neuraminidase Proteins 0.000 claims description 6
230000001932 seasonal effect Effects 0.000 claims description 6
238000009472 formulation Methods 0.000 claims description 5
239000005022 packaging material Substances 0.000 claims description 5
VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical group CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims 3
230000001747 exhibiting effect Effects 0.000 claims 2
XRQDFNLINLXZLB-CKIKVBCHSA-N peramivir Chemical compound CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(O)=O)C[C@H]1NC(N)=N XRQDFNLINLXZLB-CKIKVBCHSA-N 0.000 description 36
229960001084 peramivir Drugs 0.000 description 36
241000699670 Mus sp. Species 0.000 description 15
230000000694 effects Effects 0.000 description 8
238000007918 intramuscular administration Methods 0.000 description 8
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
239000006185 dispersion Substances 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
239000007788 liquid Substances 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
239000000243 solution Substances 0.000 description 4
231100000419 toxicity Toxicity 0.000 description 4
230000001988 toxicity Effects 0.000 description 4
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
239000003242 anti bacterial agent Substances 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
208000037797 influenza A Diseases 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
NENPYTRHICXVCS-YNEHKIRRSA-N oseltamivir acid Chemical group CCC(CC)O[C@@H]1C=C(C(O)=O)C[C@H](N)[C@H]1NC(C)=O NENPYTRHICXVCS-YNEHKIRRSA-N 0.000 description 3
239000000902 placebo Substances 0.000 description 3
229940068196 placebo Drugs 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000013543 active substance Substances 0.000 description 2
150000001450 anions Chemical class 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
239000003443 antiviral agent Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
238000011161 development Methods 0.000 description 2
238000001802 infusion Methods 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
239000002502 liposome Substances 0.000 description 2
244000005700 microbiome Species 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000003860 storage Methods 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
241000272525 Anas platyrhynchos Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
230000005526 G1 to G0 transition Effects 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
101710154606 Hemagglutinin Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
206010025080 Lung consolidation Diseases 0.000 description 1
241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
101710176177 Protein A56 Proteins 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
239000002585 base Substances 0.000 description 1
150000007514 bases Chemical class 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
229940050390 benzoate Drugs 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
150000005323 carbonate salts Chemical class 0.000 description 1
150000007942 carboxylates Chemical class 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
238000013375 chromatographic separation Methods 0.000 description 1
239000002361 compost Substances 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
239000002612 dispersion medium Substances 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000001087 glyceryl triacetate Substances 0.000 description 1
235000013773 glyceryl triacetate Nutrition 0.000 description 1
239000000185 hemagglutinin Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000011221 initial treatment Methods 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
229960003742 phenol Drugs 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
239000003340 retarding agent Substances 0.000 description 1
AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
229940086735 succinate Drugs 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
229960002622 triacetin Drugs 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Dermatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

BRPI0707769-6A 2006-02-13 2007-02-12 tratamentos antivirais intravenosos BRPI0707769A2 (pt)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US77274806P	2006-02-13	2006-02-13
US60/772,748		2006-02-13
USPCT/US2006/013535		2006-04-12
PCT/US2006/013535 WO2007117241A1 (en)	2006-04-12	2006-04-12	Intramuscular antiviral treatments
PCT/US2007/003755 WO2007095218A1 (en)	2006-02-13	2007-02-12	Intravenous antiviral treatments

Publications (1)

Publication Number	Publication Date
BRPI0707769A2 true BRPI0707769A2 (pt)	2011-05-10

Family

ID=38169715

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0707769-6A BRPI0707769A2 (pt)	2006-02-13	2007-02-12	tratamentos antivirais intravenosos

Country Status (12)

Country	Link
EP (1)	EP1986626A1 (es)
JP (3)	JP2009538822A (es)
KR (9)	KR102475176B1 (es)
CN (1)	CN104784166A (es)
AU (1)	AU2007215156A1 (es)
BR (1)	BRPI0707769A2 (es)
CA (1)	CA2642260C (es)
EA (1)	EA025483B1 (es)
HK (1)	HK1212250A1 (es)
MX (2)	MX393640B (es)
MY (1)	MY166063A (es)
WO (1)	WO2007095218A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI0707769A2 (pt) *	2006-02-13	2011-05-10	Biocryst Pharm Inc	tratamentos antivirais intravenosos
CN101367750B (zh) *	2007-08-14	2012-05-23	中国人民解放军军事医学科学院毒物药物研究所	(1s,2s,3s,4r)-3-[(1s)-1-乙酰氨-2-乙基-丁基]-4-胍基-2-羟基-环戊基-1-羧酸水合物及其医药用途
KR20220033561A (ko)	2020-09-07	2022-03-17	주식회사 경보제약	페라미비르 화합물을 포함하는 프리믹스 제형의 제약학적 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ412898A3 (cs) *	1996-06-14	1999-08-11	Biocryst Pharmaceuticals, Inc.	Substituované cyklopentanové sloučeniny, použitelné jako inhibitory neuraminidázy
PT1040094E (pt) *	1997-12-17	2009-06-03	Biocryst Pharm Inc	Compostos de ciclopentano e de ciclopenteno substituídos úteis como inibidores da neuraminidase
GB0015324D0 (en) *	2000-06-22	2000-08-16	Biota Scient Management	Medicaments
BRPI0707769A2 (pt) *	2006-02-13	2011-05-10	Biocryst Pharm Inc	tratamentos antivirais intravenosos

2007
- 2007-02-12 BR BRPI0707769-6A patent/BRPI0707769A2/pt not_active Application Discontinuation
- 2007-02-12 KR KR1020217035812A patent/KR102475176B1/ko active Active
- 2007-02-12 KR KR1020197017311A patent/KR102194015B1/ko active Active
- 2007-02-12 AU AU2007215156A patent/AU2007215156A1/en not_active Abandoned
- 2007-02-12 CN CN201510115375.7A patent/CN104784166A/zh active Pending
- 2007-02-12 KR KR1020087022406A patent/KR20080096829A/ko not_active Ceased
- 2007-02-12 EA EA200870263A patent/EA025483B1/ru unknown
- 2007-02-12 JP JP2008554421A patent/JP2009538822A/ja not_active Withdrawn
- 2007-02-12 KR KR1020217018500A patent/KR102323339B1/ko active Active
- 2007-02-12 CA CA2642260A patent/CA2642260C/en active Active
- 2007-02-12 WO PCT/US2007/003755 patent/WO2007095218A1/en not_active Ceased
- 2007-02-12 KR KR1020187005451A patent/KR101992585B1/ko not_active Ceased
- 2007-02-12 KR KR20147030611A patent/KR20140132778A/ko not_active Ceased
- 2007-02-12 KR KR1020227042429A patent/KR20230003248A/ko not_active Ceased
- 2007-02-12 KR KR1020167030296A patent/KR20160129105A/ko not_active Ceased
- 2007-02-12 MX MX2020002008A patent/MX393640B/es unknown
- 2007-02-12 EP EP07750583A patent/EP1986626A1/en not_active Ceased
- 2007-02-12 MX MX2008010394A patent/MX2008010394A/es active IP Right Grant
- 2007-02-12 KR KR1020207036259A patent/KR102267754B1/ko active Active
2008
- 2008-08-13 MY MYPI20083086A patent/MY166063A/en unknown
2013
- 2013-08-26 JP JP2013174479A patent/JP6073202B2/ja active Active
2015
- 2015-07-09 JP JP2015137495A patent/JP2015180695A/ja not_active Withdrawn
2016
- 2016-01-14 HK HK16100369.5A patent/HK1212250A1/xx unknown

Also Published As

Publication number	Publication date
MX2020002008A (es)	2020-07-13
KR20190072681A (ko)	2019-06-25
KR20230003248A (ko)	2023-01-05
KR20200143519A (ko)	2020-12-23
KR102475176B1 (ko)	2022-12-07
EP1986626A1 (en)	2008-11-05
CA2642260C (en)	2016-08-09
JP2013256527A (ja)	2013-12-26
EA200870263A1 (ru)	2009-06-30
KR20180024027A (ko)	2018-03-07
KR101992585B9 (ko)	2022-09-20
JP6073202B2 (ja)	2017-02-01
MX393640B (es)	2025-03-21
JP2009538822A (ja)	2009-11-12
KR20140132778A (ko)	2014-11-18
CA2642260A1 (en)	2007-08-23
KR102323339B1 (ko)	2021-11-08
KR20160129105A (ko)	2016-11-08
HK1212250A1 (en)	2016-06-10
KR101992585B1 (ko)	2019-06-25
MY166063A (en)	2018-05-23
WO2007095218A1 (en)	2007-08-23
KR20080096829A (ko)	2008-11-03
CN104784166A (zh)	2015-07-22
KR20210135632A (ko)	2021-11-15
EA025483B1 (ru)	2016-12-30
JP2015180695A (ja)	2015-10-15
KR20210076189A (ko)	2021-06-23
KR102194015B1 (ko)	2020-12-22
AU2007215156A1 (en)	2007-08-23
KR102267754B1 (ko)	2021-06-23
MX2008010394A (es)	2009-01-12

Legal Events

Date	Code	Title
2018-01-23	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-24	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-11-19	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2019-12-03	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2020-10-20	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2021-02-17	B09B	Patent application refused [chapter 9.2 patent gazette]
2021-04-27	B12B	Appeal against refusal [chapter 12.2 patent gazette]

Publication	Publication Date	Title
ES2145115T4 (es)	2010-06-17	Composiciones inyectables a base de derivados de taxanos.
BR112020006950A2 (pt)	2020-10-06	composições farmacêuticas injetáveis estabilizadas de l-epinefrina
US12121503B2 (en)	2024-10-22	Antiviral treatments
JP2020536089A (ja)	2020-12-10	アセトアミノフェン−プレガバリン組み合わせ及び疼痛を処置する方法
JP6073202B2 (ja)	2017-02-01	静脈におけるウイルスの治療
ES3056897T3 (en)	2026-02-25	Rifabutin compositions and method of making
JPH0269417A (ja)	1990-03-08	精神分裂病治療用組成物
JP2009538822A5 (es)	2013-10-24
PT2136816E (pt)	2015-04-13	Oleilfosfocolina
AU2013216632B2 (en)	2016-09-01	Intravenous antiviral treatments
BRPI0621552A2 (pt)	2011-12-13	tratamentos antivirais intramusculares
NZ570538A (en)	2012-03-30	Intravenous antiviral treatments
KR20080113099A (ko)	2008-12-26	근육내 항바이러스 치료